KURA ONCOLOGY, INC. (NASDAQ:KURA) Files An 8-K Other Events
Item 8.01 Other Events.
On December 8, 2019, Kura Oncology, Inc. (the “Company”) issued a press release announcing clinical and regulatory updates from its Phase 2 clinical trial of tipifarnib in patients with angioimmunoblastic T-cell lymphoma relapsed (AITL) or refractory peripheral T-cell lymphoma (PTCL). The Company presented these data at the American Society of Hematology (ASH) Annual Meeting held December 7-10, 2019 in Orlando, Florida.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Kura Oncology, Inc. Exhibit
EX-99 2 kura-ex991_6.htm EX-99.1 kura-ex991_6.htm Exhibit 99.1 Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma – Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL,…
To view the full exhibit click here
About KURA ONCOLOGY, INC. (NASDAQ:KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.